CAR T-cell therapy is advancing in solid tumors by improving target selection, trafficking, tumor-microenvironment resistance, and long-term function, but major biological barriers still require combined solutions.
- Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign
- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- Ensuring Quality Of CGT Materials
- Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials
- Ever Wonder What Running A $50B Capital Facilities Project Feels Like?
- Generative AI Can Write The Code, But Who Builds In The Quality?
- From "Live Drug" To Precision Tool: Redefining CAR T Safety
- UK's Decentralized Manufacturing Could Be A Revolution; Mind The Risk
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Lyophilization To Enable Drug Products Containing Labile Molecules
Develop lyophilized formulations to overcome stability challenges and significantly extend the shelf life of sensitive therapeutic products.
-
Scaling Success: A Blueprint For Flexible Biometrics Partnerships
Learn how a micro-FSP model and integrated biometrics team can scale from specialized support to a full-service solution, ensuring agility and consistency as clinical trial needs evolve.
-
Analytical Approach For Bispecific Antibody Quality Study
Bispecific antibody quality control demands advanced analytics to detect mispaired species, assess structural integrity, and confirm potency, ensuring safety and efficacy across diverse therapeutic applications.
-
Best Practices For Analysis Of In Vitro Transcribed (IVT) mRNA
Learn best practices for high-resolution analysis of IVT RNA using automated capillary electrophoresis. Improve accuracy and precision in quantifying critical quality attributes.
-
Best Practices For Analysis Of IVT mRNA
Discover how an automated capillary electrophoresis system provides robust and precise integrity, concentration, and size analysis for IVT mRNA.
-
Improving Bioprocess Monitoring And Control With Multivariate Data Analysis
Learn about multivariate data analysis (MVDA) techniques, like PCA and PLS, that enable near real-time monitoring, prediction, and optimization of biomanufacturing processes.
-
Scalability And Reproducibility Of The AAV9 Capture Step
Scaling gene therapies beyond rare diseases demands innovation. Discover a chromatography system that boosts efficiency, protects product integrity, and overcomes viral vector manufacturing challenges.
-
Contamination In The Shadows: Risks Lurking From Environmental Issues
Discover how science-based bio-decontamination strategies effectively eliminate invisible pathogens and rapidly restore facilities to operational safety following major infrastructure disruptions.
-
Form Fill And Seal Label Applicator For Drug Packaging
Discover a solution that ensures particularly efficient and reliable vertical and horizontal form fill and seal machine labeling.
-
A Scalable Manufacturing Platform For The Purification Of Stem Cell Derived Exosomes
EV production scale increases require paired robust, scalable, and cost-effective downstream processes. Process parameters can be tailored for therapeutic exosome programs and allow for maximum exosome recovery.
NEWSLETTER ARCHIVE
- 04.03.26 -- Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials
- 04.02.26 -- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- 04.01.26 -- The In Vivo Cell Therapy Shift On Display At PMWC 2026
- 03.31.26 -- STREAM Edition: Take The Lead With A GS Cell Line Development Kit
- 03.31.26 -- UK's Decentralized Manufacturing Could Be A Revolution; Mind The Risk
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections